Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Ergomed said it was on track to deliver annual results 'materially above' market expectations following a 'strong' start to the year.
The company said it now expected revenue and earnings (EBITDA) for the year ending 31 December 2019 to be 'materially above' current market expectations.
Trading year to date had been 'strong' in both the Clinical Research Organisation Services (CRO) and pharmacovigilance businesses.
The CRO business in particular 'has benefited from agreements with clients on change orders and projects concluding positively. Trading in PV remains solid and management expects this performance to be sustained throughout 2019,' the company said.
'We are still early in the year but we have seen an excellent start to 2019 across our business. Trading performance is strong in both CRO and PV and we continue to see the benefits of our focus on improved financial performance and profitability,' said Dr Miroslav Reljanović, Executive Chairman of Ergomed.
At 9:13am: (LON:ERGO) Ergomed Plc share price was +28p at 232p